|
2020 Journal Article Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M. A., Millward, M., Patel, S. P., Haydon, A., Johnson, D. B., Lo, S., Blank, C. U., Sandhu, S., Carlino, M. S., Larkin, J. M.G., Menzies, A. M. and Long, G. V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Annals of Oncology, 31 (8), 1075-1082. doi: 10.1016/j.annonc.2020.04.471 |
|
2019 Journal Article Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient ProgramMartin-Algarra, Salvador, Hinshelwood, Rebecca, Mesnage, Soizick, Cebon, Jonathan, Ferrucci, Pier Francesco, Aglietta, Massimo, Neyns, Bart, Chiarion-Sileni, Vanna, Lindsay, Colin R., Del Vecchio, Michele, Linardou, Helen, Merelli, Barbara, Tonini, Giuseppe, Atkinson, Victoria, Freivogel, Klaus, Stein, Dara, Dalland, Lindi, Lau, Mike, Legenne, Philippe, Queirolo, Paola and Millward, Michael (2019). Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 29 (5), 527-532. doi: 10.1097/CMR.0000000000000608 |
|
2019 Journal Article Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesPires da Silva, Ines, Glitza, Isabella C., Haydu, Lauren E., Johnpulle, Romany, Banks, Patricia D., Grass, George D., Goldinger, Simone M. A., Smith, Jessica L., Everett, Ashlyn S., Koelblinger, Peter, Roberts-Thomson, Rachel, Millward, Michael, Atkinson, Victoria G., Guminski, Alexander, Kapoor, Rony, Conry, Robert M., Carlino, Matteo S., Wang, Wei, Shackleton, Mark J., Eroglu, Zeynep, Lo, Serigne, Hong, Angela M., Long, Georgina V., Johnson, Douglas B. and Menzies, Alexander M. (2019). Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 32 (4), 553-563. doi: 10.1111/pcmr.12775 |
|
2019 Journal Article Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaJansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Foppen, M. H. Geukes, Hoejberg, L., Schmidt, H., van Thienen, J., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Makela, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., Long, G., Atkinson, , Blank, C. U. and Neyns, B. (2019). Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology, 30 (7), 1154-1161. doi: 10.1093/annonc/mdz110 |
|
2019 Journal Article Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literatureXu, Wen, Moor, Rebecca J., Walpole, Euan T. and Atkinson, Victoria G. (2019). Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Research, 29 (3), 333-337. doi: 10.1097/CMR.0000000000000586 |
|
2019 Journal Article Reply to E. Hindié and K.R. HessLong, Georgina V., Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Hauschild, Axel (2019). Reply to E. Hindié and K.R. Hess. Journal of Clinical Oncology, 37 (15), 1356-1358. doi: 10.1200/JCO.19.00004 |
|
2019 Journal Article Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialSchadendorf, Dirk, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Lesimple, Thierry, Plummer, Ruth, Schachter, Jacob, Dasgupta, Kohinoor, Manson, Stephanie, Koruth, Roy, Mookerjee, Bijoyesh, Kefford, Richard, Dummer, Reinhard, Kirkwood, John M. and Long, Georgina V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 20 (5), 701-710. doi: 10.1016/S1470-2045(18)30940-9 |
|
2019 Conference Publication Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibitionAgarwala, Sanjiv S., Ross, Merrick I., Zager, Jonathan, Shirai, Keisuki, Essner, Richard, Smithers, Bernard M., Atkinson, Victoria, Sarson, David and Wachter, Eric A. (2019). Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition. LONDON: BMC. |
|
2019 Conference Publication Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanomaTie, Emilia Nan, Lai-Kwon, Julia Elizabeth, Na, Lumine, Rtshiladze, Michael Alexander, Bozzi, James, Read, Tavis, Atkinson, Victoria, Au-Yeung, George, Long, Georgina V., McArthur, Grant A., Sandhu, Shahneen Kaur, Saw, Robyn, Walpole, Euan Thomas, Menzies, Alexander M., Smithers, B. Mark and Gyorki, David E. (2019). Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL United States, 31 May - 4 June 2019. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2018 Journal Article Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanomaHauschild, Axel, Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Long, Georgina V. (2018). Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. Journal of Clinical Oncology, 36 (35), 3441-3449. doi: 10.1200/JCO.18.01219 |
|
2018 Conference Publication Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)Weber, Jeffrey S., Mandala, Mario, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Cowey, C. Lance, Dalle, Stephane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus, Middleton, Mark R., Maio, Michele, Atkinson, Victoria, Dummer, Reinhard, de Pril, Veerle, Qureshi, Anila, Larkin, James and Ascierto, Paolo A. (2018). Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). National-Cancer-Research-Institute (NCRI) Cancer Conference, Glasgow Scotland, Nov 04-06, 2018. LONDON: NATURE PUBLISHING GROUP. |
|
2018 Journal Article Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionTio, Martin, Rai, Rajat, Ezeoke, Ogochukwu M., McQuade, Jennifer L., Zimmer, Lisa, Khoo, Chloe, Park, John J., Spain, Lavinia, Turajlic, Samra, Ardolino, Luke, Yip, Desmond, Goldinger, Simone M., Cohen, Justine V., Millward, Michael, Atkinson, Victoria, Kane, Alisa Y., Ascierto, Paolo A., Garbe, Claus, Gutzmer, Ralf, Johnson, Douglas B., Rizvi, Hira A., Joshua, Anthony M., Hellmann, Matthew D., Long, Georgina V. and Menzies, Alexander M. (2018). Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. European Journal of Cancer, 104, 137-144. doi: 10.1016/j.ejca.2018.09.017 |
|
2018 Conference Publication ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanomaAscierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanomaLong, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M. and Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19-23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.053 |
|
2018 Conference Publication CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaLipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanomaAscierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.062 |
|
2018 Conference Publication CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaLipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.058 |
|
2018 Conference Publication Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialAtkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.007 |
|
2018 Conference Publication Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trialAtkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialDummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J. M. and Long, G. V. (2018). Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
